CME Updates on Metastatic Pancreatic Cancer Guidelines Live Webinar Series and Webcourse
Metastatic pancreatic cancer is a serious malignancy that, with limited treatment options and poor outcomes, poses a growing challenge for oncologists. Increasing in incidence, it is projected to be the second-leading cause of cancer-related death before 2030. Though targeted therapies are available for a small subset of patients, advances in targeted therapies for other cancer types have been less successful with pancreatic cancer. Treatment relies primarily on chemotherapy, but novel targeted therapies and immunotherapies show promise in early phase clinical trials. To help ensure the best outcomes for patients with metastatic pancreatic cancer, Rockpointe a Clinical Education Alliance Company and the Potomac Center for Medical Education have developed a free continuing medical education CME and maintenance of board certification ABIM MOC activity designed to keep oncologists current on the latest guidance and treatment options for this deadly disease.
Clinicians may participate in one of several live webinars held in conjunction with hospital Grand Rounds, another live webinar associated with a Regional Meeting on Nov. 2, 2022, or as an enduring webcourse until July 29, 2023.
Current Grand Rounds webinar dates and times (with more to be added as they are confirmed)
Wednesday, Aug. 17, 2022
12:00 – 1:00 PM ET (11:00 – 12:00 PM CT / 9:00 – 10:00 AM PT)
Wednesday, Aug. 24, 2022
12:00 – 1:00 PM ET (11:00 – 12:00 PM CT / 9:00 – 10:00 AM PT)
Friday, Nov. 4, 2022
12:15 – 1:15 PM ET (11:15 – 12:15 PM CT / 9:15 – 10:15 AM PT)
Tuesday, Nov. 15, 2022
12:00 – 1:00 PM ET (11:00 – 12:00 PM CT / 9:00 – 10:00 AM PT)
Regional Meeting webinar date and time
Wednesday, Nov. 2, 2022
5:30 – 6:30 PM PT (8:30 – 9:30 PM ET / 7:30 – 8:30 PM CT)
With a 5-year survival rate of only 3%, metastatic pancreatic cancer is a grim diagnosis. In addition to chemotherapy, targeted therapies are an option for the approximately 20% of patients who express actionable genetic alterations. Novel targeted therapies and immunotherapies in early clinical trials provide potential future treatment options. Selection between currently available treatments and ongoing clinical trials relies heavily on biomarkers, as well as performance status, comorbidities, and patient preference. Communicating with patients regarding the importance of biomarker testing, treatment selection, and clinical trials is key to ensuring the best outcomes.
Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens is an hour-long activity designed to provide oncology clinicians with information on the most recent biomarkers and treatments for metastatic pancreatic cancer, expert recommendations for treatment selection and sequencing, and updated information on emerging biomarkers and targeted therapies for pancreatic cancer.
At the program’s conclusion, participants should be able to:
- Evaluate patients with metastatic pancreatic cancer based on current guideline recommendations for imaging and testing.
- Select evidence-based treatments for patients with metastatic pancreatic cancer accounting for patient performance, comorbidities, and preferences.
- Effectively communicate with patients with metastatic pancreatic cancer regarding genetic testing, treatment goals and preferences, and clinical trials.
- Discuss the prognostic and predictive potentials of emerging genetic tests to inform treatment selection for patients with pancreatic cancer.
- Evaluate the safety and efficacy of emerging therapies for metastatic pancreatic cancer.
This program is CME/ABIM MOC-certified and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation and is jointly provided by the Potomac Center for Medical Education and Rockpointe. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing medical education, Rockpointe/CEA is leader in educational programming with more than 27 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com and www.clinicaloptions.com
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To register for a Grand Rounds webinar, click here. To register for the Regional Meeting webinar, click here. To view the enduring webcourse, click here.